Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
HENGRUI PHARMA's Injection for Chronic Hepatitis B Treatment Included in Proposed Breakthrough Therapy List
Recommend 3 Positive 7 Negative 2 |
||||
|
||||
|
HENGRUI PHARMA (01276.HK) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd. (literal translation of "福建盛迪醫藥有限公司"), had its HRS-5635 injection included in the proposed breakthrough therapy list published by the Center for Drug Evaluation of the National Medical Products Administration. The drug is intended for the treatment of chronic hepatitis B. The company also mentioned that no similar drug has been approved for market launch either domestically or internationally, according to its inquiries. As of now, total R&D investment in the projects related to the HRS-5635 injection has reached around RMB152 million. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
